NanaBisTM - Now With Synthetic CBD and THC
Based on recommendations from the FDADATE: Friday 15th July 2022
Author:
Medlab,
Following the company’s transformation to a pureplay biotech, Medlab Clinical has focused on the development of key asset NanaBis, a 50:50 micellar formulation of CBD and THC, in the treatment of cancer-induced bone pain.
Based on recommendations from the FDA, Medlab has switched to using synthetic active pharmaceutical ingredients (APIs) in NanaBis and is imminently expected to approach the regulators for approval of a Phase III trial. We expect a recently compiled drug master file (DMF) for NanaBis to support this application. To fund its development ambitions, the company is now pursuing a dual listing on the US Nasdaq stock market, pending shareholder approval. We value Medlab at A$239.8m or A$0.70 per share.
About the author
Medlab
Medlab in-house Editor.
11-13 LORD ST, BOTANY
BUILDING A, UNIT A5 – A6, BOTANY QUARTER
NSW, 2019, AUSTRALIA
www.medlab.co
OFFICE HOURS: 8:30AM - 5PM EST
AUS: 1300 369 570
AUS: +61 2 8188 0311
USA: +1 947 771 8119
UK: +44 20 8138 0311
FAX: +61 2 9699 3347
Email: [email protected]